Gilead Ramps Up Cancer Focus With $21 Billion Immunomedics Deal

(Bloomberg) -- Gilead Sciences Inc. agreed to acquire Immunomedics Inc. for about $21 billion, a substantial premium for the maker of a promising breast-cancer therapy, in another big bet by the dr...